|
|
Volumn 108, Issue 5, 2016, Pages
|
|
Oncolytic Virus Approved to Treat Melanoma
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
IPILIMUMAB;
ONCOLYTIC VIRUS;
PEMBROLIZUMAB;
TALIMOGENE LAHERPAREPVEC;
BONE MARROW TRANSPLANTATION;
CANCER IMMUNOTHERAPY;
DRUG APPROVAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
GENE DELETION;
HEAD AND NECK CANCER;
HUMAN;
IMMUNE RESPONSE;
IMMUNE SYSTEM;
IMMUNOCOMPROMISED PATIENT;
MELANOMA;
METASTASIS;
NOTE;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
T LYMPHOCYTE;
TREATMENT RESPONSE;
MULTICENTER STUDY (TOPIC);
ONCOLYTIC VIROTHERAPY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHYSIOLOGY;
PROCEDURES;
VIROLOGY;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
MELANOMA;
MULTICENTER STUDIES AS TOPIC;
ONCOLYTIC VIROTHERAPY;
ONCOLYTIC VIRUSES;
|
|
EID: 84968909149
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djw140 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|